Allergan Rejects Hostile $53B Bid From Valeant, Ackman
Allergan Inc. said Monday its board unanimously spurned a "grossly inadequate" $53 billion exchange offer from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman, inflaming tensions as the eager suitors...To view the full article, register now.
Already a subscriber? Click here to view full article